Stockreport

Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024 [Yahoo! Finance]

Carisma Therapeutics, Inc.  (CARM) 
PDF Engineered TIM4-expressing macrophages correct defective efferocytosis in MASH, demonstrating potent anti-fibrotic activity Nov. 17, 2024 /PRNewswire/ -- Carisma Ther [Read more]